Andere Sprachen Immuneering Corporation

Aktien

A3CWDN

US45254E1073

IMRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
1.64 ^USD	+5.13%		+11.56%	-77.69%

09.04.	Immuneering Corporation präsentiert präklinische Daten auf der Jahrestagung der American Association for Cancer Research	CI
02.04.	IMMUNEERING CORPORATION : erhält Kaufen-Rating von Mizuho Securities	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	09.04.
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	09.04.
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	03.04.
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27.03.
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	27.03.
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations	27.03.
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI	20.03.
North American Morning Briefing : Investors -2-	18.03.
Sector Update: Health Care Stocks Ease Late Afternoon	15.03.
Sector Update: Health Care	15.03.
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data	15.03.
North American Morning Briefing : Inflation -2-	15.03.
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14.03.
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	14.03.
Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors	14.03.
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12.03.
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors	12.03.
Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors	12.03.
Immuneering Begins Phase 2a Testing of Potential Cancer Immunotherapy; Phase 1 Data Due Out Soon	11.03.
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors	11.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immuneering Corporation

Aktien

A3CWDN

US45254E1073

IMRX

Andere Sprachen

Filter